>
BioNTech SE logo

BNTX - BioNTech SE Share Price

$121.52 -0.6  -0.5%

Last Trade - 12/04/21

Sector
Healthcare
Size
Large Cap
Market Cap £21.52bn
Enterprise Value £20.56bn
Revenue £418.6m
Position in Universe 430th / 6825
Bullish
Bearish
Unlock BNTX Revenue
Momentum
Relative Strength (%)
1m +19.8%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -6.76%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 61.6 127.6 108.6 482.3 9,365 5,603 +98.6%
+38,228 -45.5
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BioNTechSE - ADR revenues increased from EUR108.6M to EUR482.3M.Net income totaled EUR15.2M vs. loss of EUR179.1M. Revenuesreflect Commercial revenues increase from EUR24.2M toEUR303.5M, Research & development revenues increase fromEUR84.4M to EUR178.8M. Net Income reflects Other OperatingIncome increase from EUR2.7M to EUR250.5M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BNTX Revenue Unlock BNTX Revenue

Net Income

BNTX Net Income Unlock BNTX Revenue

Normalised EPS

BNTX Normalised EPS Unlock BNTX Revenue

PE Ratio Range

BNTX PE Ratio Range Unlock BNTX Revenue

Dividend Yield Range

BNTX Dividend Yield Range Unlock BNTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BNTX EPS Forecasts Unlock BNTX Revenue
Profile Summary

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated January 1, 2008
Public Since October 10, 2019
No. of Shareholders: 2
No. of Employees: 1,941
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 241,521,065
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BNTX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BNTX
Upcoming Events for BNTX
Monday 10th May, 2021
Q1 2021 BioNTech SE Earnings Call
Monday 9th August, 2021
Q2 2021 BioNTech SE Earnings Call
Frequently Asked Questions for BioNTech SE
What is the BioNTech SE share price?

As of 12/04/21, shares in BioNTech SE are trading at $121.52, giving the company a market capitalisation of £21.52bn. This share price information is delayed by 15 minutes.

How has the BioNTech SE share price performed this year?

Shares in BioNTech SE are currently trading at $121.52 and the price has moved by 0.169k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioNTech SE price has moved by 81.3% over the past year.

What are the analyst and broker recommendations for BioNTech SE?

There are no analysts currently covering BioNTech SE.

When will BioNTech SE next release its financial results?

BioNTech SE is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the BioNTech SE dividend yield?

BioNTech SE does not currently pay a dividend.

Does BioNTech SE pay a dividend?

BioNTech SE does not currently pay a dividend.

When does BioNTech SE next pay dividends?

BioNTech SE does not currently pay a dividend.

How do I buy BioNTech SE shares?

To buy shares in BioNTech SE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioNTech SE?

Shares in BioNTech SE are currently trading at $121.52, giving the company a market capitalisation of £21.52bn.

Where are BioNTech SE shares listed? Where are BioNTech SE shares listed?

Here are the trading details for BioNTech SE:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BNTX
What kind of share is BioNTech SE?

Based on an overall assessment of its quality, value and momentum, BioNTech SE is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BioNTech SE share price forecast 2021?

Shares in BioNTech SE are currently priced at $121.52. At that level they are trading at 3.42% discount to the analyst consensus target price of 0.00.

Analysts covering BioNTech SE currently have a consensus Earnings Per Share (EPS) forecast of 22.9968890383 for the next financial year.

How can I tell whether the BioNTech SE share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioNTech SE. Over the past six months, the relative strength of its shares against the market has been 18.33%. At the current price of $121.52, shares in BioNTech SE are trading at 33.07% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioNTech SE PE Ratio?

The BioNTech SE PE ratio based on its reported earnings over the past 12 months is 1.71k. The shares are currently trading at $121.52.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of BioNTech SE?

We were unable to find the directors for BioNTech SE.

Who are the major shareholders of BioNTech SE?

Here are the top five shareholders of BioNTech SE based on the size of their shareholding:

PRIMECAP Management Company Investment Advisor
Percentage owned: 1.92% (4.63m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 1.2% (2.90m shares)
AT Impf GmbH Corporation
Percentage owned: 1.16% (2.80m shares)
Vanguard Capital Opportunity Fund Mutual Fund
Percentage owned: 0.92% (2.22m shares)
PRIMECAP Odyssey Aggressive Growth Fund Mutual Fund
Percentage owned: 0.77% (1.85m shares)
Similar to BNTX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.